Annual Report 2018/2019
CELLINK has today published its Annual Report for 2018/2019. The document is attached to this press release and is also available on https://cellink.com/investors/.
Distribution of the printed versions of the annual reports to those shareholders who have requested dispatch, will be done by mail during the week commencing 25th of November.
For further information, please contact:
Erik Gatenholm, CEO Gusten Danielsson, CFO
Phone: EU +46 73 267 00 00 Phone: +46 70 991 86 04
US +1 (650) 515 5566 US +1 (857) 332 2138
This press release and the annual report are translated from the Swedish version. When in doubt, the Swedish wording prevails.
CELLINK is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North Growth Market under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at firstname.lastname@example.org.